South Korea-based Daewoong Pharmaceutical has obtained approval for a SGLT-2 inhibitor+metformin combination drug in just one month after the release of Envlo Tab., the 1st SGLT-2 inhibitor by Korea, expanding its product portfolio.

Daewoong Pharmaceutical had announced the approval of Envlomet SR Tab. 0.3/1000mg, (ingredient name: enavogliflozin, metformin hydrochloride) on June 13th.

Envlomet SR Tab. is a combination of two drugs, enavogliflozin and metformin hydrochloride. It has been approved as an adjuvant for dietary and exercise therapies to improve blood glucose control in patients with type 2 diabetes.

Metformin is used as first-line treatment for type 2 diabetes, and enavogliflozin effectively lowers blood glucose levels with just 0.3mg, a dosage that is only 1/30 of other drugs in the same class.

Envlomet SR Tab. is a significant treatment option in the healthcare landscape where there is a growing prevalence of diabetes and the corresponding rise in the prescription of combination therapies. Combination therapies for diabetes are highly preferred and have significant market potential internationally.

Lee Chang-jae, CEO of Daewoong Pharmaceutical, said, "We will continue to expand our portfolio of combination drugs, starting with Envlomet, to meet the increasing demand for such drugs in the antidiabetic drug market."